Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system

Ten patients with advanced congestive heart failure were treated with an arginine vasopressin V1 antagonist during hemodynamic monitoring to determine the contribution of vasopressin to vasoconstriction in this disorder. The vasopressin antagonist caused a decrease in systemic vascular resistance in the three patients whose plasma vasopressin was greater than 4.0 pg/ml (average for the group was 2.4 +/- 0.6). Plasma vasopressin concentration correlated with the percent decrease of systemic vascular resistance (r = 0.70, p less than 0.025), serum sodium (r = 0.72, p less than 0.02) and serum creatinine (r = 0.85, p less than 0.005). To compare the relative roles of vasopressin, the renin-angiotensin system and the sympathetic nervous system, these patients also received captopril and phentolamine. Captopril decreased systemic vascular resistance by 20% (p less than 0.05), mostly in patients with high plasma renin activity. Levels of plasma renin activity ranged between 1 and 46 ng/ml per h (average 14.7 +/- 5.7) and correlated with serum sodium (r = 0.77, p less than 0.025), serum creatinine (r = 0.73, p less than 0.025) and right atrial pressure (r = 0.67, p less than 0.05). Phentolamine decreased systemic vascular resistance in all patients (average 34%, p less than 0.01), but the decrease did not correlate with the pretreatment norepinephrine concentration. Norepinephrine levels were elevated in all patients (694 +/- 110 pg/ml) and correlated with baseline stroke volume index (r = 0.75, p less than 0.025) and plasma renin activity (r = 0.67, p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				J. J. Finley IV, M. A. Konstam, and J. E. Udelson Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia Circulation, July 22, 2008; 118(4): 410 - 421. [Full Text] [PDF]

				J. E. Udelson, F. A. McGrew, E. Flores, H. Ibrahim, S. Katz, G. Koshkarian, T. O'Brien, M. W. Kronenberg, C. Zimmer, C. Orlandi, et al. Multicenter, Randomized, Double-Blind, Placebo-Controlled Study on the Effect of Oral Tolvaptan on Left Ventricular Dilation and Function in Patients With Heart Failure and Systolic Dysfunction J. Am. Coll. Cardiol., June 5, 2007; 49(22): 2151 - 2159. [Abstract] [Full Text] [PDF]

				M. A. Konstam, M. Gheorghiade, J. C. Burnett Jr, L. Grinfeld, A. P. Maggioni, K. Swedberg, J. E. Udelson, F. Zannad, T. Cook, J. Ouyang, et al. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial JAMA, March 28, 2007; 297(12): 1319 - 1331. [Abstract] [Full Text] [PDF]

				E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2397 - 2409. [Abstract] [Full Text] [PDF]

				S. R. Goldsmith and M. Gheorghiade Vasopressin Antagonism in Heart Failure J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1785 - 1791. [Abstract] [Full Text] [PDF]

				J. F. Price, J. A. Towbin, S. W. Denfield, S. Clunie, E.O. Smith, C. J. McMahon, B. Radovancevic, and W. J. Dreyer Arginine Vasopressin Levels Are Elevated and Correlate With Functional Status in Infants and Children With Congestive Heart Failure Circulation, June 1, 2004; 109(21): 2550 - 2553. [Abstract] [Full Text] [PDF]

				G. S. Francis and W. H. W. Tang Vasopressin Receptor Antagonists: Will the "Vaptans" Fulfill Their Promise? JAMA, April 28, 2004; 291(16): 2017 - 2018. [Full Text] [PDF]

				S. R. Goldsmith Vasopressin antagonists in CHF: ready for clinical trials? Cardiovasc Res, April 1, 2002; 54(1): 13 - 15. [Full Text] [PDF]

				J. E. Udelson, W. B. Smith, G. H. Hendrix, C. A. Painchaud, M. Ghazzi, I. Thomas, J. K. Ghali, P. Selaru, F. Chanoine, M. L. Pressler, et al. Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure Circulation, November 13, 2001; 104(20): 2417 - 2423. [Abstract] [Full Text] [PDF]

				Y. Oikawa, K. Maehara, T. Saito, K. Tamagawa, and Y. Maruyama Attenuation of angiotensin II-mediated coronary vasoconstriction and vasodilatory action of angiotensin-converting enzyme inhibitor in pacing-induced heart failure in dogs J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1188 - 1194. [Abstract] [Full Text] [PDF]

				P. R Kalra, S. D Anker, and A. J.S Coats Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin Cardiovasc Res, August 15, 2001; 51(3): 495 - 509. [Full Text] [PDF]

				W. T. Abraham Pharmacologic Management of Chronic Heart Failure: A Review Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 168 - 190. [Abstract] [PDF]

				L. M. Burrell, P. A. Phillips, J. Risvanis, R. K. Chan, K. L. Aldred, and C. I. Johnston Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat Am J Physiol Heart Circ Physiol, July 1, 1998; 275(1): H176 - H182. [Abstract] [Full Text] [PDF]

				P. Medina, A. Acuna, J. B. Martinez-Leon, E. Otero, J. M. Vila, M. Aldasoro, and S. Lluch Arginine Vasopressin Enhances Sympathetic Constriction Through the V1 Vasopressin Receptor in Human Saphenous Vein Circulation, March 10, 1998; 97(9): 865 - 870. [Abstract] [Full Text] [PDF]

				A. Tahara, Y. Tomura, K.-I. Wada, T. Kusayama, J. Tsukada, M. Takanashi, T. Yatsu, W. Uchida, and A. Tanaka Pharmacological Profile of YM087, A Novel Potent Nonpeptide Vasopressin V1A and V2 Receptor Antagonist, in Vitro and in Vivo J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 301 - 308. [Abstract] [Full Text]

				S. Sakai, T. Miyauchi, T. Sakurai, Y. Kasuya, M. Ihara, I. Yamaguchi, K. Goto, and Y. Sugishita Endogenous Endothelin-1 Participates in the Maintenance of Cardiac Function in Rats With Congestive Heart Failure : Marked Increase in Endothelin-1 Production in the Failing Heart Circulation, March 15, 1996; 93(6): 1214 - 1222. [Abstract] [Full Text]

				A. J. Manolis, C. Olympios, M. Sifaki, S. Handanis, M. Bresnahan, I. Gavras, and H. Gavras Suppressing Sympathetic Activation in Congestive Heart Failure : A New Therapeutic Strategy Hypertension, November 1, 1995; 26(5): 719 - 724. [Abstract] [Full Text]